Published on 15 Aug 2023 on Simply Wall St. via Yahoo Finance

Some Analysts Just Cut Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates

One thing we could say about the analysts on HOOKIPA Pharma Inc. (NASDAQ:HOOK) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Revenue estimates were cut sharply as the analysts signalled a weaker outlook - perhaps a sign that investors should temper their expectations as well.

After the downgrade, the consensus from HOOKIPA Pharma's seven analysts is for revenues of US$15m in 2023, which would reflect a measurable 4.4% decline in sales compared to the last year of performance. Per-share losses are expected to explode, reaching US$1.10 per share. However, before this estimates update, the consensus had been expecting revenues of US$19m and US$1.09 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also making no real change to the loss per share numbers.

View our latest analysis for HOOKIPA Pharma